Most patients with hepatitis C who were recent injection drug users achieved sustained virologic response after treatment with direct-acting antiviral Epclusa, according to recently published study results.
“In the USA and Europe, some jurisdictions have restrictions for the reimbursement of DAA therapy for people with recent illicit drug or alcohol use or those receiving opioid substitution therapy, irrespective of disease stage. The scarcity of data on DAA treatment outcomes in these populations has been used as a rationale for such restrictions,” Jason Grebely, PhD, from the Kirby Institute, University of New South Wales, Sydney, and colleagues wrote. “Data from this phase 4 SIMPLIFY study show high adherence and SVR among people who have injected drugs in the past 6 months.”
Supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
American Heart Association Scientific Sessions
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.